ArticleAbdominal radiology (New York)2026
Contrast-enhanced ultrasound and clinical features for preoperative prediction of GPC-3 expression in hepatocellular carcinoma.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preoperative Prediction of Glypican-3 Expression in Hepatocellular Carcinoma Using Sonazoid Contrast-Enhanced Ultrasound Radiomics.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGlypican 3 (GPC-3) in hepatocellular carcinoma (HCC) is receiving attention as a potential biomarker for treatment options. However, GPC-3 expression can only be assessed through surgical pathology. Therefore, we aim to develop and validate a practical tool based on contrast-enhanced ultrasound (CEUS) and clinical features to preoperatively identify GPC-3 expression in HCC.
methodsFrom August 2021 to July 2024, 197 patients with pathologically confirmed HCC were retrospectively enrolled. The least absolute shrinkage and selection operator (LASSO) and stepwise logistic regression analyses were performed in training cohort to identify predictors and establish a model for predicting GPC-3 expression. The performance of model was evaluated by C-index, area under the receiver operating characteristic curve (ROC), calibration curves, and decision curve analysis (DCA).
resultsOur study showed that heterogeneous arterial phase hyperenhancement (APHE), mosaic architecture, alpha-fetoprotein (AFP) ≥ 100 ng/mL, rim enhancement in arterial phase (AP), neutrophil count (Nc) level and age were independently associated with GPC-3 expression. The model demonstrated strong predictive performance and the areas under curve were 0.811 (95% confidence interval[CI]: 0.737-0.885) and 0.750 (95%CI: 0.622-0.878) in training and validation cohorts. Good calibration and prominent net benefit were exhibited in both cohorts. Moreover, The risk score calculated by the model presented promising stratification ability between high-risk and low-risk groups in terms of relapse-free survival (RFS) .
conclusionBased on CEUS and clinical features, the model can help identify GPC-3 expression accurately and may provide valuable preoperative insights for customizing personalized treatment planning in HCC patients.
Indexed as
Identifiers
41575493What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.